Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 prophylaxis (children) meta-analysis

kidCOVE (part 2)
 
NCT04796896
RCTSpikevax (Moderna mRNA-1273 COVID-19 vaccine)placeboCOVID-19 prophylaxis (children)NA
3005/997 suggested
  • suggested 74 % decrease in confirmed COVID (any severity)
  • suggested 88 % decrease in symptomatic Covid-19
press realease March 23,2022 : - interim analysis showed a robust neutralizing antibody response in both age groups (6 month -2 years and 2 years to 6 years) after a 25 µg two-dose primary series of mRNA-1273 along with a favorable safety profile.- Using the Phase 3 COVE study COVID-19 definition, vaccine efficacy in children 6 months to 2 years was 43.7% and vaccine efficacy was 37.5% in the 2 to under 6 years age group
teenCOVE (P203) (Adolescents 12-17Y)
 
NCT04649151
RCTSpikevax (Moderna mRNA-1273 COVID-19 vaccine)placeboCOVID-19 prophylaxis (children)some concern
2489/1243 suggested
  • suggested 93 % decrease in confirmed COVID (any severity) with a moderate degree of certainty due to some concern in risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).